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Biologic activity of equine infectious anemia virus (EIAV) surface (SU) glycoprotein was assayed in a mouse model. Recombinant SU
from virulent EIAV17 (SU17), administered intraperitoneally to mouse pups, induced dose-dependent diarrheal responses similar to those
reported for SIV SU (Virology 277 (2000) 250). SU17 caused fluid accumulation without histological lesions in mouse intestinal loops,
induced chloride secretory currents in Ussing chambers and increased inositol 1,4,5 triphosphate (IP3) levels in HT29 cells. An SU17 peptide,
SU17(299–330), provoked a dose-dependent diarrheal response akin to enterotoxic peptides from SIV. In contrast, SU from an avirulent EIAV
strain failed to induce a dose response in mouse pups and produced lower levels of activity than SU17 in Ussing chambers and IP3 assays.
These results demonstrate that a mouse pup model is useful to monitor EIAV SU biologic activity, showing clear differences between the
activities of SU derived from virulent and avirulent viruses, and may provide a useful screen of EIAV virulence.
D 2004 Elsevier Inc. All rights reserved.
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Equine infectious anemia virus (EIAV) is a macrophage-
tropic lentivirus that causes a disease whose progression is
relatively rapid when compared to other lentiviruses
(Montelaro et al., 1993; Sellon et al., 1994). The course of
disease is divided into 3 stages (acute, chronic, and
inapparent) that describe the commonly observed interac-
tions between pathogen and host. Acute disease generally
develops within the first month post-infection and is
characterized by fever, thrombocytopenia, and high titer0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2004.12.022
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A&M University, College Station, TX 77843, USA.viremia (Montelaro et al., 1993; Sellon et al., 1994). The
initial febrile episode usually resolves, but in rare cases may
be fatal. Some animals will then enter the chronic stage of
disease, experiencing multiple febrile episodes at irregular
intervals. Chronic EIA can be life threatening and has been
compared to the severe wasting syndrome associated with
AIDS in humans and SAIDS in rhesus macaques (Mon-
telaro et al., 1993). Clinical symptoms of chronic EIA
include lethargy, edema, anemia, weight loss, and diarrhea
(Montelaro et al., 1993). Horses surviving chronic EIA enter
the inapparent carrier stage; these animals present as
clinically normal, yet remain infected and can transmit
virus to naive animals (Montelaro et al., 1993).
To map the major virulence determinants of EIAV and to
identify specific host-pathogen interactions that result in
disease versus life-long inapparent infection, we have
employed two related EIAV clones that produce virus
stocks with strikingly different virulence phenotypes.
EIAV17 causes severe disease within 5 to 7 days post-
infection in experimentally infected Shetland ponies (Payne
et al., 1998), while animals infected with 10-fold higher05) 132–144
J.M. Ball et al. / Virology 333 (2005) 132–144 133doses of EIAV19 remain clinically healthy (Payne et al.,
1994). EIAV17 and EIAV19 share identical gag, pol, tat and
S2 sequences but differ in their LTRs, env and rev
sequences, with the regions of greatest sequence divergence
occurring in SU and the U3 enhancer (Payne et al., 2004).
Chimeric clones designed to define the major virulence
determinants of EIAV17 show both env and LTR sequences
are required for the acute virulence phenotype, as replacing
either env or LTRs with those of EIAV19 abrogates virulence
(Payne et al., 2004). Further, it appears SU plays a greater
role in virulence than TM as EIAV17 containing TM from
EIAV19 causes disease, whereas EIAV17-containing SU
from EIAV19 does not (Payne et al., 2004).
The mechanisms of EIAV-induced disease remain
obscure, but recent evidence suggests that virally-induced
cytokines cause several clinical abnormalities associated
with EIAV infection as significant increases in interleukin
(IL)-6, tumor necrosis factor (TNF)-a, and transforming
growth factor (TGF)-h have been demonstrated in EIAV-
infected horses (Sellon et al., 1998; Swardson et al., 1997;
Tornquist et al., 1997). In studies that support the role of
cytokines in disease, we have recently demonstrated a
correlation between virulence phenotype and virally-
induced increases of cytokine expression in equine mono-
cyte-derived macrophages (eMDM) (Lim et al., 2005). The
acutely virulent EIAV17 induces significant increases in
gene expression of IL-1a, IL-1h, IL-6, IL-10, and TNF-a,
whereas avirulent EIAV19 fails to induce any of these
cytokines above control levels (Lim et al., 2005). Maximum
cytokine induction occurs 0.5 to 1 h post-infection
implicating virus binding as the trigger for altered gene
expression. Thus, both in vivo and in vitro studies implicate
EIAV env gene products as important contributors to
disease and further suggest EIAV SU may play an
important role in virulence through activation of cell
signaling pathways.
The binding of primate lentiviral SU to cell surface
receptor (CD4) and co-receptor (CCR5 and CXCR4)
molecules facilitates virus entry and activates an array of
signal transduction pathways, thus, contributing to disease
induction. Activation of signaling pathways can result in
increased expression of cytokines and chemokines, T-cell
activation and entry into cell cycle, reorganization of
cytoskeletal structures leading to changes in cell motility
and polarization, activation of ion channels, and induction
of virus expression from resting CD4+ T cells (Bossis et al.,
2002; Cicala et al., 2002; Kinter et al., 2003; Liu et al.,
2000; Popik and Pitha, 2000; Yi et al., 2004).
HIV SU also interacts with cell types other than Tcells and
macrophage to activate signaling pathways that may contrib-
ute to disease. For example, HIV SU has neurotoxic effects
and likely plays a role in HIV-associated dementia. HIV SU
increases intracellular calcium [Ca2+]i, activates phospholi-
pase C and inhibits cyclic AMP, inducing apoptosis and
injury of ganglions and neurons in culture (Dreyer et al.,
1990; Zheng et al., 1999). Other effects of SU on glial cellsinclude enhanced expression of ICAM-1 through activation
of protein kinase C and tyrosine kinase (Shrikant et al., 1996)
and induction of IL-1 and TNF-a (Koka et al., 1995).
Increased caspase-3 proteolytic activity and mitochondrial
release of cytochrome c are also reported in cerebrocortical
cultures exposed to the HIV SU (Garden et al., 2002; Kaul et
al., 2001). Many of the toxic activities of SU are mediated
through chemokine receptors (Meucci et al., 1998).
HIV SU has also been shown to mobilize [Ca2+]i in
cultured intestinal epithelial cells, engaging GPR15/Bob, a
G protein-coupled receptor that is abundant on at the basal
surface of the intestinal epithelium to mediate strain specific
SU-induced Ca2+ signaling (Clayton et al., 2001; Dayanithi
et al., 1995; Maresca et al., 2003). In cultured epithelial
cells, the response is blocked by HIV V3-specific neutraliz-
ing antibodies and is diminished by pre-treating the cells
with neurotensin, an agonist of Cl secretory currents via
IP3-mediated [Ca2+]i mobilization (Dayanithi et al., 1995).
We recently reported that purified SIV SU elicits a specific,
dose-dependent diarrheal response in mice in the absence of
histological alterations and promotes Cl secretory currents
across unstripped intestinal mucosa by a calcium-mediated
pathway (Swaggerty et al., 2000). Thus, in addition to its
other recognized activities, SIV SU meets all of the criteria
of an enterotoxin. Similar to the HIV data, the enterotoxic
domain of SIV SU overlaps the V3 region and functions
similar to neurotensin (Swaggerty et al., 2000, 2004).
To determine if the signaling and/or enterotoxic activities
of SU were peculiar to the primate lentiviruses and to further
assess the roles of EIAV SU in viral pathogenesis, we
examined its biologic activity in our previously described
mouse pup assay (Swaggerty et al., 2000). SU from EIAV17
and EIAV19 were produced in Spodoptera frugiperda (Sf9)
cells using a baculovirus expression system and were
purified by nickel-nitriloacetic (Ni-NTA) affinity chroma-
tography. The purified proteins were examined for enter-
otoxic and signaling activities. We show that EIAV SU
derived from an acutely virulent virus has similar biological
properties to those recently ascribed to SIV and HIV SU
while SU from an avirulent virus is less active. Notably, the
two EIAVs are derived from molecular clones and differ
only in env and LTRs; both viruses replicate to high titer,
with cytopathic effects, in eMDM. In this study we show
recombinant SU from EIAV17 meets the definition of an
enterotoxin, generating Cl secretory currents across
intestinal epithelia and fluid accumulation in the absence
of histological alterations, in a mouse model system. SU
from EIAV19 is a less active enterotoxin than SU from
EIAV17, strongly suggesting that the virulence phenotypes
of the parental viruses are related to the ability of their
respective SUs to activate signal transduction pathways.
While SIV and HIV SU also have been shown to function as
viral enterotoxins, various virus strains have been used and
to our knowledge no direct comparisons between related
cloned viruses with different virulence phenotypes have
been made. Finally, we identify an enterotoxic peptide
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an SIV SU enterotoxic peptide.Results
Production and characterization of recombinant SU
Two infectious molecular clones of EIAV were used as
the sources of SU sequences. SU19 was derived from clone
pSPeiav19 that produces the avirulent virus stock EIAV19
(Payne et al., 1994) and SU17 was derived from clone p19/
wenv17 that produces the highly virulent virus EIAV17
(Payne et al., 1998). These two viruses differ only in env and
LTRs; their SU proteins differ by 30 amino acids as shown in
Fig. 1. We initially expressed EIAV SU using its native
amino terminus to direct protein secretion; however, the
recombinant SU was not secreted from Sf9 cells (data not
shown). Thus, to facilitate purification, we employed an
amino terminal his-tag; the SU coding region commenced
with amino acid 7, a tyr present at the amino terminus of
mature, virion-associated SU (Ball et al., 1988). The vast
majority of recombinant SU was cell-associated and
purification was performed by metal chelate chromatogra-
phy. The purity of recombinant SU17 (hisSU17) and SU19
(hisSU19) ranged from 70 to 90% by SDS–PAGE (Fig. 2,
Panel A). The size of hisSU17 was 75 to 110 kDa while
hisSU19 was somewhat smaller at 65 to 90 kDa. To
determine the extent of glycosylation of recombinant SU,
baculovirus-infected Sf9 cells were cultured in the presence
of 1 Ag/ml tunicamycin. In the presence of tunicamycin, both
hisSU19 and hisSU17 were approximately 52-kDa, very close
to the calculated 53-kDa molecular weight for the SU peptide
backbone (Fig. 2, Panel B). As hisSU17 contains 19 potential
N-linked glycosylation sites and hisSU19 contains only 13
such sites the size difference of the recombinant proteins is
likely due to differences in their extent of glycosylation.Fig. 1. A comparison of the deduced amino acid sequence of SU17 and SU19. SU
EIAV17 and SU19 is derived from clone pSPeiav19 that produces the avirulent sto
SU17 is shown in full; identical residues in SU19 are indicated with dots. An ar
terminus of virion-associated SU (Ball et al., 1988); hisSU constructs were gener
EIAV SU contains a principal neutralizing domain (PND) and is noted as a bo
SU17(299–300) is also boxed. Peptide SU17(298–316) is indicated by an overline and
previously described EIAV SU-specific monoclonal antibodies (86, 87, and 98) (HisSU17 and hisSU19 also were probed by Western
blotting with previously characterized mouse monoclonal
antibodies to further assess their integrity. Both proteins were
recognized by monoclonal antibodies (Fig. 2, Panel C) that
have been mapped to amino acids 50–58, 231–239, and 270–
279 of SU (Ball et al., 1992) suggesting that hisSU17 and
hisSU19 are full-length and glycosylated and that any
biologic activities demonstrated by these proteins might
reasonably be expected to reflect activities of native viral SU.
SU derived from virulent EIAV induced a dose-dependent
diarrheal response in a mouse pup model
Since induction of diarrhea in neonatal mouse pups has
been shown as an efficient method to monitor activation of
signal transduction pathways (Ball et al., 1996; Swaggerty
et al., 2000), recombinant SU was inoculated intraperito-
neally (IP) into 6- to 8-day-old Balb/C mouse pups and
monitored for diarrhea induction. Varying doses of hisSU17
and hisSU19 were tested in 6 to 10 mouse pups per dose.
The onset of diarrhea was typically within 2 h post-exposure
and continued for up to 8 h, occasionally for up to 24 h,
similar to that seen previously with SIV SU (Swaggerty et
al., 2000). As shown in Fig. 3 (Panel A), the incidence of
diarrhea ranged from 0% to 83% following administration
of 0.025 nmol to 0.2 nmol of purified hisSU17 indicative of
a dose response. The diarrhea dose 50 (DD50) was
determined to be 0.14 nmol based on the calculations of
Reed and Muench (1938). This value is essentially identical
to that previously reported for SIVmac239 SU (Swaggerty et
al., 2000). Diarrhea was the only visible sign of illness in the
experimental animals; pups maintained normal levels of
activity as well as normal body temperatures. The diarrhea
response to EIAV SU was specific, as administration of
control proteins had no effect. When the same doses of
hisSU19 were tested some animals did exhibit diarrhea,
however a 50% point was not reached nor was there any17 is derived from clone p19/wenv17 that produces the virulent virus stock
ck EIAV19 (Payne et al., 1994, 1998). The deduced amino acid sequence of
row marks the tyrosine residue previously identified as the mature amino
ated as in-frame fusions to this tyrosine residue. Variable region 3 (V3) of
xed region. The region corresponding to the enterotoxic synthetic peptide
peptide SU17(313–328) is indicated by a dashed underline. Binding sites for
Ball et al., 1992) are indicated.
Fig. 2. SDS–PAGE and Western blot analyses of recombinant hisSU. Panel
A shows Coomassie stained gels (lanes a–d) and Western blots (lanes e–g)
of purified hisSU17 (lanes b and e), hisSU19 (lanes c and f) and glycoproteins
from baculovirus infected cells (lanes d and f). SDS–PAGE standards are
shown in lane a. (Panel B) HisSU-baculovirus-infected Sf9 cells were
cultured in the presence of tunicamycin to inhibit glycosylation. Cell lysates
were prepared from tunicamycin-treated (+) and untreated () hisSU-
expressing cells and were analyzed by Western blot using equine immune
serum. Treatment with tunicamycin resulted in recombinant SU products of
reduced size; the sizes of unglycosylated hisSU were similar indicating that
the difference in apparent molecular weight between hisSU17 and hisSU19
seen in Panel Awas due to a difference in the extent of glycosylation of the
proteins. Panel C shows Western blots of purified hisSU19 and hisSU17 with
a panel of monoclonal antibodies whose reactivities with EIAV SU have
been previously mapped (Ball et al., 1992); recognition sites of the
monoclonal antibodies are indicated in Fig. 1. Reactivity of each re-
combinant protein with monoclonal antibodies 86 (lanes a), 87 (lanes b), and
98 (lanes c), along with apparent molecular weight by SDS–PAGE, were
used as an indication that the recombinant proteins were full length.
Fig. 3. EIAV SU-mediated diarrhea induction. HisSU17, hisSU19, or peptides
were diluted in 50 Al of endotoxin-free PBS and injected IP into 6- to 8-day-
old Balb/C mice pups. Pups were monitored for diarrhea every 2 h for 10 h.
The x axis is dose administered; y axis is percentage of mouse pups scoring
positive for diarrhea. The numbers of pups tested at each dose are indicated.
Panel A. Diarrhea in SU17-treated pups ranged from 0% to 83% at doses of
0.025 to 0.2 nmol; the DD50 was calculated to be 0.14 nmol (Reed and
Muench, 1938). A 50% point was not reached for hisSU19 and no diarrhea
was scored at a 1-nmol dose. At 0.025 to 0.2 nmol doses significantly fewer
hisSU19-treated animals ( P = 0.05, chi square (v
2)) developed diarrhea than
those administered the same dose of hisSU17. PBS and glycoproteins from
Baculovirus-infected Sf9 cells served as negative controls. Panel B. Diarrhea
induction mediated by synthetic peptides. Diarrhea in SU17(299–330)-treated
pups ranged from 0% to 83%. The calculated DD50 was 54.4 nmol. Peptides
SU17(298–316) SU17(313–328) and SU19(300–331) were tested at doses of 100 nmol
only. An SIV negative control peptide (Swaggerty et al., 2004) was used at a
dose of 50 nmol.
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when any two doses were compared. At all tested doses
significantly fewer animals (P = 0.05, chi-square (v2))
developed diarrhea when administered hisSU19 than those
administered the same dose of hisSU17 (Fig. 3, Panel A). In
an effort to induce diarrhea in at least 50% of the pups, 6
animals were administered 1 nmol of hisSU19. No diarrhea
was induced in this group of mice despite the increased
dose. The animals administered 1 nmol of hisSU19 were
lethargic the first 4 h of the experiment; however, the control
animals given the same concentration of total glycoproteins
from wt baculovirus-infected cells were also lethargic. This
J.M. Ball et al. / Virology 333 (2005) 132–144136was probably due to the high concentration of protein
administered.
Virulent and avirulent SU induced fluid accumulation in
mouse intestinal loops
Recombinant SU derived from either avirulent EIAV19
or the virulent EIAV17 was introduced into 4- to 6-week-
old Balb/C mouse intestinal loops to monitor protein-
specific fluid accumulation. The average hisSU17-treated
loops were 60.8 mg/cm compared to an average of 55.4
mg/cm for the hisSU19-treated loops, and 45.6 mg/cm for
the PBS control (Fig. 4). Four out of seven (67%) of the
hisSU17-treated loops were statistically heavier/length due
to an accumulation of fluid when compared to PBS
control-treated loops (Student’s t test, P b 0.05), whereas
only one out of four (25%) of the loops treated with
hisSU19 were statistically heavier/length than the controls.
Similar to SIVmac239 SU loop data (Swaggerty et al.,
2000), when the average g/cm were compared, there were
no significant differences in the 3 groups of animals
however a positive trend was noted (Fig. 4).
No histological lesions were observed in SU-treated
intestinal loops
Tissues from the intestinal loops were analyzed for the
presence of histological alterations by hematoxylin and
eosin staining (Fig. 5). The mucosa of the EIAV SU-treated
intestinal loops (Figs. 5B and C) appeared identical to the
PBS-treated loops (Fig. 5A). No significant lesions were
observed within the mucosa of any specimens examined
from the treatment groups indicating SU lacked cytolytic
activity; the columnar epithelia cells were intact and anig. 4. EIAV SU-mediated fluid accumulation in mouse intestinal loops. For
ach treatment, (PBS, hisSU19, or hisSU17), individual loop values are
dicated by the open circles. The average g/cm for each treatment is
dicated by the horizontal bar. The n value indicates the number of loops
nalyzed for each treatment. There were no significant differences in the





aequivalent number of goblet cells were present. Hence, the
diarrhea induction in the mouse pup model was not due to
intestinal damage by SU.
Cl secretory current measurements by Ussing chamber
To begin to evaluate the signaling mechanism induced by
hisSU17 resulting in diarrhea and to directly compare
virulent and avirulent SU activity, Cl secretory currents
were measured across unstripped mouse intestinal mucosa
in modified micro-Ussing chambers (0.04 cm2 aperture).
Tissue reactivity to known agonists, 10 AM forskolin (FSK),
a cAMP agonist (Frizzell and Morris, 1994), and 10 AM
carbachol (Cch), a calcium agonist (n = 8), was first
established. As expected, the mean change in short circuit
current (DIsc) response to FSK was 20.1 F 3.9 AAmps/cm2
while the addition of Cch following FSK resulted in a mean
DIsc 3.0 F 0.81 AAmps/cm2 above that of FSK (Table 1).
Stimulation of Cl conductance by the cAMP agonist
elicited a sustained level of secretion, such that the activated
currents were not time-dependent and the current to voltage
relationship was linear; the calcium agonist elicited a
smaller, transient DIsc.
Prior to the addition of hisSU17 or hisSU19, 10 AM FSK
induced a mean DIsc of 25.8 F 3.2 or 22.8 F 2.6 AA/cm2,
respectively. Once the FSK response was stable, purified
hisSU17 (1.5 AM) was added to both the apical and
basolateral surfaces of the ileal tissues, which induced a
mean DIsc of 2.3 F 0.47 AA/cm2 above that of FSK. The
DIsc with the virulent SU overlapped the DIsc seen with the
calcium agonist Cch (above). Addition of 1.5 AM hisSU19
both apically and basolaterally induced a mean DIsc of 1.0F
0.46 AA/cm2 above the FSK response, which failed to
overlap with the Cch response and was 59% of (or 1.3-fold
less) than that induced by hisSU17 (Table 1). Taken together
there was a clear difference in the activity of SU derived
from virulent and avirulent EIAV clones when monitored by
micro-Ussing chamber. The secretory current elicited by
SU17 indicates an agonist activity similar to that of Cch.
Resistance was maintained throughout the experiment with
the mean tissue conductance maintained at 22.3 F 5.6
mSem/cm2. All responses to agonists were sensitive to
bumetanide.
SU increased IP3 levels in HT-29 colonic cells
Since the micro-Ussing chamber data suggested a Cch-
like (calcium-mediated) response was induced by hisSU17, a
competitive radioreceptor assay was utilized to measure IP3
levels in HT-29 cells treated with EIAV SU. Purified
hisSU17 (150 nM) increased IP3 levels 2.3-fold, whereas
hisSU19 (150 nM) only increased IP3 levels 1.5-fold above
basal levels of mock-treated control cells (Fig. 6). Neuro-
tensin (10 nM) served as the positive control and increased
IP3 levels 1.7-fold above basal levels. Cells treated with
glycoproteins from wt baculovirus-infected Sf9 cells had
Fig. 5. Hematoxylin and eosin staining of the mucosa from mouse intestinal loops. Panel A shows a PBS-treated loop, panel B shows a hisSU19-treated loop
and panel C shows a SU17-treated loop. All loops show normal columnar epithelium and intact brush border microvilli (black, closed arrows). All loop sections
also have similar numbers of goblet cells (white, open arrows) indicating that no histological lesions were induced by administration of either hisSU19 or
hisSU17 to the loops.
J.M. Ball et al. / Virology 333 (2005) 132–144 137IP3 levels comparable to mock treated cells. These data
showed an increase of IP3 by virulent EIAV SU akin to
SIVmac239 SU (Swaggerty et al., 2000). The greater
concentration of IP3 induced by hisSU17 when compared
to hisSU19 indicates the agonist activity of SU from the
virulent clone is more robust and supports the diarrhea and
Ussing chamber data.
Identification of a biologically active peptide sequence in
EIAV SU
Selection of peptide sequences
In our previous studies of the enterotoxic activity of SIV
SU (Swaggerty et al., 2004), we identified and synthesizedTable 1






















2.3 F 0.47 20.7 F 5.3 22.3 F 5.6
FSK 22.8 F 2.6
FSK + SU19
(n = 6)
1.0 F 0.46 21.6 F 6.2 23.0 F 5.4
a Forskolin (FSK) was added alone and the tissue response was monitored.
Only those intestinal mucosal segments with a positive FSK response
(second column), a conductance of ~20 mSem/cm2, and maintenance of
resistance were used to analyze the response to carbachol (Cch, a known
calcium agonist), SU17, or SU19 (column 3).
b The change in short-circuit current (DIsc) was calculated by subtracting
the increase in Isc measurement from the background DIsc obtained
immediately before the addition of agonist (expressed in AA/cm2). The
mucosal tissues were challenged with 10 AM FSK.
c After the FSK response was stable, the tissue was challenged with a
second agonist and the change in Isc above that of FSK was measured.
d Conductance was noted at 30 min post challenge and at 60 min.
e Post challenge in mS/cm2 to ensure the integrity of the tissue over the
course of the experiment.31-residue peptides (see Table 2) that were predicted to fold
as an amphipathic helix based on computer algorithms.
These peptides exhibited biologic activities similar to those
of full-length SU in our mouse pup model (Swaggerty et al.,
2004). The EIAV SU sequence was examined for a peptide
with similar overall charge, equivalent number of polar and
hydrophobic residues and/or predicted structure as those of
the SIV enterotoxic peptides. Similar to the SIV peptides,
amino acids 299–330 of SU17 (SU17(229–330)) contains 9
charged residues with a net +3 charge, 4 residues with amine
side chains (Gln/Asn), 5 amino acids with highly polar side
chains (OH or SH) and two putative N-linked glyco-
sylation (NXS/T) sites (Table 2). The amphipathic score
(AS) of the EIAV peptide was lower than those of the SIV
peptides.
Comparison of the SU amino acid sequences from the
virulent and avirulent EIAV clones revealed this domain
differed extensively (10 amino acids over 32 residues)
between the two viral SU proteins (Table 2). While the netFig. 6. EIAV SU-induced IP3 in HT-29 cells. The x axis is the treatment
administered (n = 3 or 4). The y axis is the fold increase in IP3 levels above
background levels in untreated cells. Addition of 150 nM hisSU17 or
hisSU19 increased IP3 levels 2.3- and 1.5-fold, respectively. The positive
control, neurotensin (10 nM), increased IP3 levels 1.7-fold. Baculovirus
glycoproteins did not increase IP3 levels above the basal levels.
Table 2
Comparison of enterotoxic lentiviral SU peptides and controls
Peptide Sequencea DD50 in mouse pup model
SU19 (300–331) DNKGVVRGDYTACNVRLLNINRKDYTGIYQVP No activity detected
b
SU17 (299–330) DNKGVIRGNSTICKVNITEIKRKDYTGIYQVP 54 nmol
SU17 (298–316) EDNKGVIRGNSTICKVNIT Not determined
c
SU17 (313–328) VNITEIKRKDYTGIYQ No activity detected
b
SIVmac239
d DAIKEVKQTIVKHPRYTGTNNTDKINLTAPG 15 nmold
SIVsmmPBj41
d KAIQEVKETLVKHPRYTGTNKTEQIKLTAPG 42 nmold
SIVmac (496–525)
d DYKLVEITPIGLAPTDVKRYTTGGTSRNKR No activity detectedb,d
a Peptide sequences are aligned around anNXTmotif (bold, underlined)with strongh-turn potential (Ptz 1.43) andX corresponding to a polar or charged residue.
Thismotif is present in all of the SU enterotoxic peptides. A secondNXT (bold) lackingh-turn potential (P tz 1.07)withX = hydrophobic residue is also indicated.
b No diarrhea was detected at a dose of 100 nmol.
c A DD50 was not determined; however, diarrhea was scored in 43% of mouse pups receiving a 100 nmol dose.
d Swaggerty et al., 2004.
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groups of the EIAV peptides were similar, there were
differences in the distribution of turn potentials (Pt) (Chou
and Fasman, 1978), the number of hydoxylated/sulfated
residues and occurrence of potential N-linked glycosylation
(NXS/T) sites. The N-termini of both SU17(299–330) and
SU19(300–331) had a strong calculated Pt of 1.43 and a
moderately predicted turn at the C-termini (Pt = 1.27). The
most striking difference in sequences corresponding to the
virulent and avirulent viruses is in the central region of the
peptides. The presence of an NXT motif that is predicted to
form a h-turn (Pt = 1.43), with a polar or charged residue
occupying position X, is present in the SU17 peptide but is
absent from the SU19 peptide.
SU17(299–330) induces a dose-dependent diarrhea in mouse
pups
To determine if the peptides functioned similarly to the
full-length protein, SU17(229–330) and SU19(330–331), a
control peptide or PBS were independently inoculated IP
into 6 to 8 day old Balb/C mouse pups and the pups
monitored for diarrhea. Upon administration of 10 nmol of
SU17(299–330), 16.7% of the pups developed diarrhea while
there was no diarrhea in animals administered control
peptide or PBS (Fig. 3, Panel B). Similar to the intact
hisSU17 protein, the onset of diarrhea was typically within
2 h post administration and continued for up to 8 h. As
seen in Fig. 3 (Panel B), the response to SU17(299–330) was
dose dependent with the incidence of diarrhea ranging
from 0 to 83% in response to 1 to 100 nmol of SU17
peptide; the DD50 for SU17(299–330) was 54.4 nmol. When
the SU19(330–331) peptide was tested at the 100 nmol dose,
no diarrhea was observed and therefore additional doses
were not completed with the avirulent peptide. These data
confirmed the agonist activity of SU17 and localized part
of the activity to residues 299–330. Subsequently, two
additional overlapping peptides corresponding to the
N- and C-terminal regions of SU17(299–330) (SU17(298–316)
and SU17(313–328)) were synthesized and administered IP at
a dose of 100 nmol to further delineate the active region
of SU17(299–330). SU17(298–316) induced diarrhea in 43% ofthe pups, whereas SU17(313–328) failed to induce diarrhea
(Fig. 3, Panel B). These data further delineate at least part
of the active domain to residues 299–316, although the
shorter peptide was not as active as that of SU17(299–330)
or the full-length protein.Discussion
HIV and SIV SU activate signal transduction pathways
upon binding to receptor and co-receptor molecules and in
doing so can alter host-cell gene expression with effects on
virus replication, immune responses and disease expression
(Cicala et al., 2002; Kinter et al., 2000; Popik and Pitha,
2000; Yi et al., 2004). Among the many activities ascribed
to primate lentivirus SU, stimulation of Cl secretory
currents and IP3-mediated Ca2+ mobilization have been
well documented (Clayton et al., 2001; Dayanithi et al.,
1995; Liu et al., 2000; Maresca et al., 2003; Swaggerty et
al., 2000). In the current report we demonstrated that EIAV
SU likewise activates signaling events, thus this property
may be common to lentiviral SU impacting fundamental
aspects of virus replication and disease.
Although there are many approaches to monitor cell-
signaling activities, a neonatal mouse diarrhea model has
allowed quick and convenient assessment of the biologic
activity of recombinant HIV and SIV SU (Ball and Estes,
unpublished; Swaggerty et al., 2000, 2004). Due to the
scarcity of equine-specific reagents and difficulties associ-
ated with equid experimental models, we tested the mouse
model as a potential measure of cell-signaling activities of
EIAV SU. Diarrhea, which is easy to discern in mouse pups,
provides a global indicator of abnormal ion flux that can be
induced by signaling, enterocyte damage, or other mecha-
nisms. It was noted that SU from a virulent EIAV strain but
not from an avirulent EIAV strain induced diarrhea in the
mouse pups prompting further investigation of SU bio-
logical properties.
Comparison of diarrhea induction by EIAV SU17 and
SIVmac239 SU should provide insight into the functional
similarities of the two glycoproteins. In fact SU17 and
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induction. The calculated DD50 was 0.14 nmol for SU17,
essentially identical to the DD50 of SIVmac239 SU (0.13
nmol) (Swaggerty et al., 2000). A dose of 0.2 nmol of each
SU induced diarrhea in about 80% of the test animals, and
the onset and duration of the diarrhea response was similar.
Based on these initial results, it became clear some of the
functional activities of SU17 corresponded to the primate
lentivirus SU.
Although the precise mechanism is unknown, diarrhea
induction by SU17 could result from direct cytopathic effects
of hisSU or more likely, from induction of Cl secretory
currents secondary to [Ca]i mobilization as shown for SIV
SU and the first described viral enterotoxin, rotavirus NSP4
(Ball et al., 1996). Mouse intestinal loops treated with
hisSU17 showed no cytopathic effects or histological
alterations, akin to what was observed following SIV SU
or rotavirus NSP4 treatment, indicating EIAV SU17 fulfills
the first criteria of an enterotoxin and functions via a non-
cytolytic, signaling pathway.
To determine if EIAV SU promotes secretory currents
across intestinal mucosa and thereby fulfills the definition of
an enterotoxin (Sears et al., 1995), micro-Ussing chamber
studies were completed under established physiological
conditions. EIAV SU17 elicited Cl
 secretory responses
across unstripped mouse ileal segments at levels comparable
to SIV SU and the known calcium agonist, carbachol,
whereas SU19 induced significantly lower currents. These
data confirmed the enterotoxic activity of EIAV SU and
indicated SU17 functions through a calcium secondary
messenger. This deduction is reasonable given HIV-1 SU
induces [Ca]i mobilization from caffeine-sensitive stores in
HT-29 colonic cells (Dayanithi et al., 1995), and has been
put forward as a mechanism of gastrointestinal dysfunction
in AIDS patients (Kotler et al., 1984).
Although the mobilization of [Ca]i by SU17 was not
directly determined, IP3 levels were monitored pre- and
post- SU17 treatment to determine if the same signaling
pathway induced by SIV and HIV SU was likewise
activated by EIAV SU17. Previous data show the addition
of neurotensin, an agonist of Cl secretion via IP3-mediated
calcium mobilization, ablates the HIV SU calcium response
in HT-29 cells and suggests HIV SU induces a similar
pathway (Dayanithi et al., 1995). Since molecules that
mobilize [Ca]i generally function by activating phospholi-
pase C (PLC) to stimulate the production of IP3 (Berridge
and Irvine, 1984), and elevated levels of IP3 then bind ER
receptors to elicit the release of stored calcium, IP3 levels
are a reasonable indicator of [Ca]i mobilization promoted by
the PLC pathway. Elevation of IP3 by SU17 (2.26-fold
increase) was found comparable to SIV SU (1.6-fold
increase) and rotavirus NSP4 (3.67-fold increase) (Dong et
al., 1997; Swaggerty et al., 2000). Hence, EIAV SU17-like
SIV SU and rotavirus NSP4 activates PLC resulting in
increased IP3 levels, mobilized [Ca]i, and Cl
 secretory
currents.In contrast to the SU data from the virulent EIAV
clone, SU derived from the avirulent viral clone failed to
induce significant diarrhea and no dose response was
observed. Even when the dose of SU19 was increased to
1.0 nmol, no diarrhea was observed, clearly differentiating
the activity of SU17 from SU19. In addition, IP3 levels
were reduced, and induction of Cl currents was
significantly lower than that of SU17 or carbachol. To
our knowledge, this is the first report of a direct
comparison of the functional activity of EIAV SU
glycoproteins derived from cloned, phenotypically distinct
viruses showing different in vitro activity that reflect the
in vivo virulence phenotypes.
To identify the active domain of SU17, we focused on
divergent regions of the virulent and avirulent SU proteins
and identified a region in V6, C-terminal to the SIV V3
loop, with similarities to SIV enterotoxic peptides (Swagg-
erty et al., 2004). Specifically, the EIAV SU17(299–330)
peptide contains a net +3 charge, 4 residues with amine
side chains, two putative N-linked glycosylation sites and 5
polar amino acids, identical to SIVmac239(352–382). In
addition, these regions are predicted to be amphipathic,
albeit the amphipathic score (8.0, window of 7) is relatively
low. When examined in the mouse pup model, EIAV
SU17(298–316) had a calculated DD50 of 54 nmol similar to
the enterotoxic peptides from SIVmac239 and SIVPBj41,
which have DD50s of 15 nmol and 42 nmol respectively
(Swaggerty et al., 2004). EIAV SU19(230–331) induced
random diarrheal responses, resembling the response to
hisSU19. To further delineate the SU17 active domain,
smaller peptides (SU17(298–316) and SU17(313–328)) were
prepared and tested for diarrhea induction. SU17(298–316)
induced diarrhea in 43% of pups while an equivalent
amount of SU17(313–328) failed to induce diarrhea. These data
indicate the active region is in the N-terminus of the longer
SU17(298–330) peptide.
Although the EIAV SU17(299–330) was originally selected
for synthesis based on overall charge, predicted amphi-
pathic character and the presence of a centrally located
tyrosine residue (similar to an enterotoxic SIV peptide), a
comparison of the enterotoxic and inactive SU peptides
listed in Table 2 suggests that these criteria alone are poor
predictors of enterotoxic activity for lentiviral SU glyco-
proteins. Rather, a region of high h-turn potential (Pt,
1.43, Chou and Fassman, 1978) corresponding to a
potential N-linked glycosylation site (NXT where X is
polar or charged) is found in all of the enterotoxic
lentiviral SU peptides (Table 2). Peptides lacking the
N-glycosylation site associated with a strong turn potential,
SU19(300–331), SU17(313–328), and SIVmac239control(496–525)
also lacked diarrheagenic activity (Table 2). The presence
of a second potential N-linked glycosylation site that does
not overlap a predicted h-turn (X = hydrophobic residue
with a Pt V 1.07) does not appear to contribute to function
as exemplified by the non-active SU17(313–328) peptide
lacking the first turn/glycosylation site motif but contain-
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se is clearly not required for enterotoxic activity of the
synthetic peptides, bulky glycan chains can induce local
changes in protein structure and dynamics, in particular in
receptor binding (Mandal and Mukhopadhyay, 2001).
Likewise, small protein conformational changes can
influence the extent of glycosylation (Galan et al., 2003).
The carbohydrate may protrude from the protein backbone
and hinder the lateral association with other proteins. The
lower DD50 of the enterotoxic EIAV peptide (over 300-
fold less active) when compared to full-length SU17 is
comparable to the lower activity of the SIV and NSP4
peptides when compared to the activity of their full-length
proteins (Ball et al., 1996; Swaggerty et al., 2004).
Reduced functional activity of synthetic peptides may
reflect a lack of secondary and/or tertiary folding, lack of
the full active domain, absence of modifications such as
glycosylation, or the presence of multiple signaling
domains in the parent protein. Short peptides often lack
native structure corresponding to the parental proteins
(Shoemaker et al., 1985). Limited SIVmac239 structural
studies show the peptide is predominantly random coil in
aqueous solution, but significantly increases in alpha-
helical content upon interacting with specific lipid moieties
(Huang et al., 2004; Swaggerty et al., 2004). It is unclear if
the structure of EIAV SU17(299–330) would likewise change
in a different environment or upon interacting with other
molecules. Taken together, different EIAV SU glycosyla-
tion patterns may alter localized protein structure that
influence function.
HIV and SIV SU enteropathic activity correlates with
observed diarrhea and wasting in infected humans and
nonhuman primates (Swaggerty et al., 2000, 2004). In the
EIAV-infected horse, diarrhea is occasionally observed and
comparison to the AIDS wasting syndrome has been noted
(Montelaro et al., 1993). However, we have not observed
notable diarrhea during acute infection of Shetland ponies
with high doses of the virulent EIAV17 (Payne et al., 2004)
and thus, do not suggest that effects on gut epithelial cells
are directly associated with disease induction by this virus
strain. Rather, we propose that the mouse model provides a
convenient assay for the ability of SU proteins from
various EIAV strains to induce signaling responses in other
cells such as macrophages. The limited availability of
equine cell lines and equine-specific reagents makes this
an extremely attractive prospect and we continue to
correlate responses in the mouse system to disease
induction in equids. In this regard, we recently reported
EIAV17 but not EIAV19 induces rapid induction of pro-
inflammatory cytokines in equine monocyte-derived mac-
rophages (Lim et al., 2005). Akin to the primate
lentiviruses, EIAV SU apparently interacts with a common
receptor present in murine intestine, equine macrophage,
and human cultured colonic cells. HIV SU-induced [Ca]i
mobilization is inhibited by galactosylceramide (GalCer)-
specific antibodies in HT-29 cells (Dayanithi et al., 1995),but the presence of alternate SU receptors in the mouse
intestine remains unknown. Replication of EIAV17 is
restricted to equine macrophages, but we have shown the
virus enters multiple cell types in culture (Payne and
Fuller, unpublished) indicating a more promiscuous bind-
ing event than previously realized.
EIAV clones differing only in SU dramatically vary
in their ability to induce acute disease in a Shetland
pony model (Payne et al., 2004) providing solid
evidence of the importance of EIAV SU in viral
pathogenesis. We now show the SUs from these viruses
also vary in their ability to induce diarrhea in neonatal
mice. Thus, it appears a simple and accessible mouse
pup model could prove useful in screening the biologic
activities of EIAV SU.Materials and methods
Expression and purification of recombinant EIAV SU
The infectious molecular clones pSPeiav19 (Payne et
al., 1994) and p19/wenv17 (Payne et al., 1998) were used
as the sources of SU sequences that were produced in a
baculovirus expression system. SU sequences were




product, a 1320-bp fragment, extends from amino acids
7 through 446 of the env open reading frame, beginning
with the tyrosine found at the mature amino terminus of
SU (Ball et al., 1988). It was digested with BamHI and
KpnI and cloned in-frame into pFastBacHT (Invitrogen),
which contains an amino-terminal histidine-tag, a 7-amino
acid spacer and a TEV protease recognition site.
Recombinant pFastBacHT plasmids were transformed into
Escherichia coli DH5a. Plasmid DNA was prepared using
QIAprep spin columns (Qiagen). Restriction enzyme
digestion was used to identify recombinant plasmids
and DNA sequence analysis was performed to confirm
the desired products. Bacmids were produced according
to the manufacturer’s suggested protocols (Invitrogen)
and were introduced into Sf9 cells using Cellfectin
Reagent (Invitrogen).
Sf9 cells were obtained from Invitrogen and grown in
Grace’s Insect Cell Culture Medium supplemented with 500
mg/L calcium chloride, 2800 mg/L potassium chloride, l-
glutamine, 3330 mg/L lactalbumin hydrolysate, 3330 mg/L
yeastolate and 10% fetal bovine serum (Bio Whittaker).
Suspension Sf9 cells were maintained in spinner flasks in
Express Five serum-free medium supplemented with 10 Ag/
ml gentamycin and 0.1% Pluronic F-68 (Invitrogen) at a
density of 1  106 cells/ml and grown to the required cell
density in spinner flasks. The spinner flasks were incubated
at 27 8C with constant stirring at 80–90 rpm.
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analysis of cell culture supernatants or total cell lysates.
Large-scale production of SU proteins was achieved by
infection of Sf9 cells (at a density of 2  106 cells/ml)
with recombinant baculovirus at a multiplicity of infection
of 10. Infected Sf9 cells were harvested at 72 or 96 h
post-infection and spun at 500  g for 5 min to collect
cell pellets. Cell pellets were either lysed immediately or
stored at 80 8C. To determine the extent of SU
glycosylation, Sf9 cell were infected with recombinant
baculovirus in the presence of 1 Ag/ml tunicamycin
(Sigma).
Ni-NTA chromatography
Recombinant baculovirus-infected Sf9 cells were lysed
in 5 volumes of ice-cold buffer containing 50 mM Tris–Cl
(pH 6.5), 5 mM 2-mercaptoethanol, 100 mM KCl, 1 mM
phenylmethylsulfonyl fluoride, 1% Igepal CA-630 (Sigma
Chemical) using a tissue homogenizer. Lysates were
clarified by centrifugation at 10,000  g for 10 min at
4 8C and the supernatant was applied to Ni-NTA Agarose
(Qiagen) pre-equilibrated with Buffer A (20 mM Tris–HCl
(pH 8.5), 500 mM KCl, 20 mM imidazole, 5 mM
2-mercaptoethanol, 10% (vol/vol) glycerol). The column
was washed with 10 volumes of Buffer A followed by 2
volumes of Buffer B (20 mM Tris–HCl (pH 8.5), 1 M
KCl, 5 mM 2-mercaptoethanol, 10% (vol/vol) glycerol).
His-tagged proteins were eluted with 8 volumes of a
gradient of 0 to 200 mM imidazole in 20 mM Tris–HCl
(pH 8.5), 100 mM KCl, 5 mM 2-mercaptoethanol, 10%
(vol/vol) glycerol. Column fractions were analyzed by
SDS–PAGE and appropriate fractions were pooled, dia-
lyzed, and concentrated by ultrafiltration.
SDS–PAGE and Western blot analysis
Proteins were separated on 10 or 12% SDS–PAGE
minigels and were visualized with Coomassie Brilliant Blue
G-250. To perform Western blot analysis, proteins were
transferred onto nitrocellulose membranes. Primary anti-
bodies were either equine immune sera or previously
characterized mouse monoclonal antibodies (Ball et al.,
1992). Secondary antibodies were horseradish peroxidase
conjugates (Sigma) and were detected using the ECL
Western blotting detection system (Amersham). Chemilu-
minescence was detected by exposure to X-Omat AR film
(Kodak).
Selection of peptides
Synthetic peptide sequences were selected based on
algorithms that predict hydrophilicity (Parker et al.,
1986), turn potential (Pt) (Chou and Fasman, 1978)
and amphipathic structure (Margalit et al., 1987), as well
as similarities to the SIVmac239 enterotoxic peptide(Swaggerty et al., 2004). Peptide sequences calculated
to be hydrophilic with at least one strongly predicted
h-turn, a region of amphipathic potential and a net
positive charge were evaluated for synthesis. Three
peptides were prepared corresponding to the SU17
sequence and evaluated for enterotoxic (agonist) activity:
SU17(298–316) (EDNKGVIRGNSTICKVNIT), SU17(299–330)
(DNKGVIRGNSTICKVNITEIKRKDYTGIYQVP) and
SU17(313–328) (VNITEIKRKDYTGIYQ). These peptides
overlap a previously designated EIAV variable region
and immunodominant epitope (Ball et al., 1992). A fourth
peptide (SU19(300–331); DNKGVVRGDYTACNVRLL-
NINRKDYTGIYQVP) was synthesized that corresponds
to SU17(299–330) but was based on the sequence of the
avirulent virus EIAV19. SU19(300–331) differs from the
SU17(299–330) by 10 amino acids (as indicated with an
underline).
Peptide synthesis and characterization
Peptides were synthesized by fluorenylmethoxycarbonyl
(Fmoc) solid-phase chemistry using an automated Millipore
9050 Plus Synthesizer (Perceptive Biosystems) and were
cleaved from the solid support by incubation with 90%
trifluoroacetic acid (TFA), 5% thioanisole, 3% ethanedi-
thiol, and 2% anisole. The peptide/resin mixture was filtered
through a Buchner funnel (20C fritted disc), precipitated
with ethyl ether a minimum of four times, dried under
compressed nitrogen gas, solubilized in 10% glacial acetic
acid and lyophilized. Unwanted byproducts and organic
contaminants were removed from the crude peptide by large
scale, gravimetric gel filtration chromatography (Sephadex
G-25 M, Sigma). Eluted peptide peaks were detected at 220
nm using an ISCO model 229 UV/VIS detector, pooled
separately, lyophilized, analyzed by reverse-phase HPLC
(Beckman System Gold) on a C4 Delta Pak column
(Waters) and characterized by MALDI/Time of flight mass
spectroscopy (Laboratory for Biological Mass Spectro-
scopy, Department of Chemistry, Texas A&M University).
Only peptides of the correct theoretical mass and corre-
sponding to N90% purity were used in this study.
Endotoxin assay
Purified SU, control proteins, peptides and PBS were
assayed for the presence of endotoxin using the Limulus
Amebocyte Lysate (LAL) test (Associates of Cape Cod,
Inc.) in endotoxin-free flint (soda lime) glass tubes accord-
ing to the manufacturer’s protocol. The number of EU/ml
was calculated for the samples and a value of 0.5 EU/ml or
less was considered acceptable for use in our experiments.
Mouse inoculation and diarrhea scoring
Balb/C pregnant dams or newborn litters acquired from
Harlan Sprague–Dawley were housed at Texas A&M
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Facility. Animal studies complied with all relevant federal
guidelines and institutional policies. To evaluate diarrhea
induction in a mouse pup model, purified EIAV SU derived
from the virulent EIAV17 or the avirulent EIAV19 (SU17 or
SU19, respectively) was diluted in 50 Al of sterile,
endotoxin-free PBS and injected IP into 6 to 8 day old
pups as previously described (Ball et al., 1996; Swaggerty et
al., 2000, 2004). To determine if the diarrheal response was
dose-dependent, 0.025 to 0.2 nmol of SU17 or SU19 was
administered to 67 pups (5–10 pups/group). Total glyco-
proteins from wildtype (wt) baculovirus-infected Sf9 cells
or PBS were administered to pups as negative controls.
Following injection, the pups were monitored for diarrhea
every 2 h for 10 h and then again at 24 h post injection. The
pups were monitored by one person who scored the diarrhea
on a scale of 1 to 4 according to previously established
criteria (Ball et al., 1996; Swaggerty et al., 2000).
Similarly, synthetic peptides were prepared in sterile,
endotoxin-free PBS and administered IP in a total volume of
50 Al. A C-terminal Norwalk virus peptide (residues 464–
483, DTGRNLGEFKAYPDGFLTCV) shown to be non-
diarrheagenic in other studies was used as a negative control
(Ball et al., 1996; Swaggerty et al., 2000). Diarrhea was
monitored and scored by the same criteria as the intact
protein.
Intestinal loops
To evaluate if SU would influence fluid accumulation in
closed intestinal segments, small intestinal loops (ileum and
a portion of the jejunum) were prepared in 4- to 6-week-old
Balb/C mice as described (Swaggerty et al., 2000, 2004).
The intestinal loops of the test animals were injected with 50
Al containing 0.20 nmol SU17 or SU19; control animals
received 50 Al PBS or purified HPIV2 F (another viral
protein expressed in baculovirus and previously established
as a control, (Swaggerty et al., 2000)). Following a 3-h
recovery period, the animals were humanely euthanized and
the intestinal loops were removed, weighed and measured.
A ratio of weight in g to length in cm was calculated for
each of the SU treated loops then compared to the g/cm ratio
of control loops. An un-manipulated segment of intestine
adjacent to the intestinal loop was removed from each
animal to serve as an individual control for histological
evaluation.
Histological analysis
Selected virulent and avirulent SU-treated loops were
fixed by immersion in 10% neutral buffered formalin for 24
h. Representative sections of the jejunum and the ileal loop
were trimmed, placed in Path Cassette IV tissue cassettes
(Curtis Matheson Scientific) and processed as previously
described (Swaggerty et al., 2000, 2004). After processing,
the tissues were embedded on end in paraffin blocksutilizing a Tissue-Tek console (Miles Scientific). Three to
five Am coronal sections of each segment were cut on a
Leitz Model 1512 rotary microtome (Ernst Leitz Wetylan
GMBHA), deparaffinized, rehydrated, and stained with
instant hematoxylin (Shandon) and eosin (Sigma) as
reported (Swaggerty et al., 2000). The coronal sections
were then examined for loss of cell integrity or other
histological alterations utilizing an Olympus BH-2 micro-
scope (Olympus Optical Co. LTD).
Cl secretory current measurements by Ussing chamber
To confirm the enterotoxic or agonist activity of EIAV
SU, Cl secretory currents across intact mouse mucosa were
evaluated in micro-Ussing chambers (Physiologic Instru-
ments). Short-circuited current (Isc), resistance and voltage/
potential difference were monitored continuously (Acquire
and Analyze software, V. 1.2, Physiologic Instruments)
under conditions of ionic, osmotic and electrical (automatic
voltage-clamped) equilibrium. In short, 18- to 23-day-old
Balb/C mice were humanely euthanized and approximately
4 cm of ileum were removed. The isolated ileum was cut
longitudinally into segments 6–8 mm long and mounted
unstripped onto the micro-Ussing chamber sliders (aperture
of 0.04 cm2) as described (Swaggerty et al., 2000). Tissues
were equilibrated 30 min at 37 8C in Krebs–Ringer
bicarbonate buffer (115 mM NaCl, 4.7 mM KCl, 1.13
mM MgCl2, 10 mM glucose, 1.15 mM Na2H2PO4, 25 nM
NaHCO3) with continuous bubbling of 95% O2 and 5%
CO2. The apical (mucosal) bath then was replaced with
N-methyl-d-glucamine (NMDG)-Krebs sodium-free buffer
(120 mM NMDG, 1.13 mM MgCl2, 4.7 mM KCl, 10 mM
glucose, 1 nM KH2PO4, 25 mM choline bicarbonate
[2-hydroxyethyl] trimethyl-ammonium) to minimize the
effects on Isc of cAMP-stimulated, electrogenic Na
+-glucose
co-transport across the intestinal cells (Grubb, 1995). An
increase in Isc (DIsc) in AAmps and potential difference in
volts across the intestinal mucosa under the conditions
utilized indicate chloride secretion (Sears et al., 1995).
Initially, the tissues were challenged with 10 AM FSK (in
DMSO), a known cAMP agonist followed by 10 AM Cch,
(in dH2O), a known colenergic agonist that mobilizes
[Ca2+]i and promotes a serosal to mucosal flux of Cl

resulting in an increased Isc as measured by a computer
interface (Dharmsathaphorn and Pandol, 1986; Frizzell and
Morris, 1994; Grubb, 1999). The change in short circuit
current (DIsc) was calculated by subtracting the stimulated
Isc from the Isc measured immediately prior to the addition
of agonist. Once the conditions were established with
known cAMP and calcium agonists, tissues were treated
with 1.5 AM SU17 or SU19 following 10 AM FSK and
monitored for chloride secretory currents (DIsc). All experi-
ments had a minimum of n = 6 and resistance was
monitored throughout the experiment to ensure the integrity
of the tissue remained intact. Finally, sensitivity to 400 AM
bumetanide, antagonist to the basolateral Na+-K+-2Cl
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following each experiment (Frizzell and Morris, 1994;
MacVinish et al., 1993).
IP3 measurements
As described previously (Swaggerty et al., 2000), HT-29
cells were grown to confluency in 6-well dishes, washed
and incubated with 10 mM LiCl (10 min, room temperature)
to inhibit inositol-1-phosphatase. The LiCl was discarded
and the cells treated for 45 sec with either 150 nM EIAV
SU17 or SU19, or 10 nM neurotensin prepared in Na-
HEPES-buffered saline (140 mM NaCl, 4.7 mM KCl, 1.13
mMMgCl2, 10 mM HEPES, 10 mM glucose, 1 mM CaCl2).
After the reaction was stopped with 0.2 to 0.3 volumes of
ice cold 20% perchloric acid, the cells were scraped from
the plate, sonicated for 2 min, incubated on ice for 20 min
and centrifuged at 16,000  g, 4 8C for 15 min. The
supernatant was removed and neutralized with 10 M KOH.
The newly formed precipitate was pelleted as above and the
supernatant assayed for IP3 by a competitive radioreceptor
assay (Amersham Pharmacia Biotech) according to the
manufacturer’s instructions. Radioactivity was measured for
4 min using a 1600 TR Tri-Carb liquid scintillation analyzer
(Packard Instrument Company).Acknowledgments
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